drugset / Trial / NCT04078191

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

NCT04078191

Phase 2 Terminated 20 enrolled Navidea Biopharmaceuticals
NaSingle-groupOpen-labelDiagnostic

Summary

This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.

Timeline

Start
2021-09-14
Primary completion
2024-07-09
Completion
2024-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tilmanocept Diagnostic / imaging agent 150 ug
Subject Tilmanocept Diagnostic / imaging agent 370 mbq

Indications